Tecfidera pushes Biogen revenue 40% higher in 2014
This article was originally published in Scrip
On its way to becoming Biogen Idec's top-selling product, the oral multiple sclerosis (MS) drug Tecfidera (dimethyl fumarate) helped push the company's total revenue 40% higher on a year-over-year basis to $9.7bn for 2014.
You may also be interested in...
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
The performance of 29 biopharma firms that launched IPOs during the first half of 2020 is staggering compared with 28 drug developers that went public in the first half of 2019 with a 10% average return.